The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

Life Sciences

Volumn 74, Issue 16, 2004, Pages 1999-2008

  Ryan, Martina C M ^a   Flanagan, Susan ^b   Kinsella, Una ^b   Keeling, Frank ^b   Thakore, Jogin H ^c  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

^c St Vincent's Hospital Ireland   (Ireland)

Author keywords

Atypical antipsychotics; Cortisol; Imaging; Obesity; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HYDROCORTISONE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ABDOMEN; ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD; BODY COMPOSITION; BODY FAT; BODY MASS; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIPID STORAGE; MALE; METABOLISM; OBESITY; SCHIZOPHRENIA; TOMOGRAPHY; WEIGHT GAIN;

EID: 1142285313     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.08.044     Document Type: Article

References (48)

1. Ackerman S., Nolan L.J. Body weight gain induced by psychotropic drugs. CNS Drugs. 9:1998;135-151.
2. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry. 60:1999;215-220.
3. Allison D.B., Janet L., Mentore M.S., Moonseong H., Chandler L., Cappelleri J.C., Infante M., Weiden P. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 156:1999;1686-1695.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
5. Arnow B., Kenardy J., Agras W.S. The Emotional Eating Scale: the development of a measure to assess coping with negative affect by eating. International Journal of Eating Disorder. 18:1995;79-90.
6. Banki C.M., Bissette G., Arato M., O'Connor L., Nemeroff C.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. American Journal of Psychiatry. 144:1987;873-877.
7. Banki C.M., Karmasci L., Bissette G., Nemeroff C.B. CSF corticotropin releasing hormone, somatostatin and thyrotropin releasing hormone in schizophrenia. Psychiatry Research. 43:1992;13-21.
8. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatrica Scandinavia. 100:1999;3-16.
9. Beasley C.M. Jr., Tollefson G.D., Tran P.V. Safety of olanzapine. Journal of Clinical Psychiatry. 58(Suppl. 10):1997;13-17.
10. Bjorntorp P. The regulation of adipose tissue distribution in humans. International Journal of Obesity. 20:1996;291-302.
11. Bouchard C., Despres J.-P., Mauriege P.O. Genetic and non-genetic determinants of regional fat distribution. Endocrine Reviews. 14:1993;72-93.
12. Crow S., Kendall D., Praus B., Thuras P. Binge eating and other psychopathology in patients with type II diabetes mellitus. International Journal of Eating Disorders. 30:2001;222-226.
13. Cunnah D., Jessop D.S., Besser G.M., Rees L.H. Measurement of circulating corticotropin-releasing factor in man. Journal of Endocrinology. 113:1987;123-131.
14. Dewan M.J., Pandurangi A.K., Boucher M.L., Levy B.F., Major L.F. Abnormal dexamethasone suppression test results in chronic schizophrenic patients. American Journal of Psychiatry. 139:1982;1501-1503.
15. Garrow J.S. Obesity: definition, assessment and dietary management. Grossman A. Clinical Endocrinology. 1998;943-951 Blackwell Science, Oxford.
16. Godin G., Shephard R.J. A simple method to assess behaviour in the community. Canadian Journal of Applied Sports Sciences. 10:1985;141-146.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. 1976;534-537 US Department of Health, Education and Welfare, Washington, DC.
18. Hansen B.C. The metabolic syndrome X. Annals of the New York Academy of Sciences. 892:1999;1-24.
19. Hill J.O., Wyatt H.R., Reed G.W., Peters J.C. Obesity and the Environment: Where do we go from here? Science. 299:2003;853-855.
20. Holsboer F. The endocrinology of mental disease. Grossman A. Clinical Endocrinology. 1998;1096-1116 Blackwell Science, Oxford.
21. Killaspy H., Banerjee S., King M., Lloyd M. Non-attendance at psychiatric outpatient clinics: communication and implication for primary care. British Journal of General Practice. 49:1999;880-883.
22. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., Pollmacher T. Body weight gain and plasma leptin levels during treatment with antipsychotic drugs. American Journal of Psychiatry. 156:1999;312-314.
23. Kvist H.B., Chowdhury U., Grangard U., Tylen U., Sjostorm L. Total and visceral tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. American Journal of Clinical Nutrition. 48:1988;1351-1361.
24. Lammers C.H., Garcia-Borrreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls. Biological Psychiatry. 38:1995;803-807.
25. Meltzer H.Y., Davidson M., Glassman A.H., Vieweg W.V. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Journal of Clinical Psychiatry. 63(Suppl. 9):2002;25-29.
26. Morlino M., Martucci G., Musella V., Bolzan M., de Girolamo G. Patients dropping out of treatment in Italy. Acta Psychiatrica Scandinavia. 92:1995;1-6.
27. Olfson M., Hansell S., Boyer C.A. Medication noncompliance. New Directions in Mental Health Services. 73:1997;39-49.
28. Ottoson M., Vikman-Adolfson K., Enerback S., Olivecrona G., Bjorntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism. 79:1994;820-825.
29. Overall J.E., Gorham D.R. The Brief Psychiatric Rating scale. Psychological Reports. 10:1962;799-812.
30. Pedersen S.B., Jonier M., Richelsen B. Characterisation of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism. 78:1994;1354-1359.
31. Peeke P.M., Chrousos G.P. Hypercortisolism and obesity. Annals of the New York Academy of Sciences. 771:1995;665-676.
32. Rebuffe-Scrive M., Lundholm K., Bjorntorp P. Glucocorticoid binding of human adipose tissue. European Journal of Clinical Investigation. 15:1985;267-272.
33. Roe L., Strong C., Whiteside C., Neil A., Mant D. Dietary intervention in primary care: validity of the DINE method of assessment. Family Practice. 11:1994;375-381.
34. Ryan M.C.M., Thakore J.H. Physical consequences of schizophrenia. Life Sciences. 71:2002;239-257.
35. Seidell J.C., Bjorntorp P., Sjostrom L., Sannerstedt R., Krotkiewski M., Kvist H.B. Regional distribution of muscle and fat mass in men. New insight in to the risk of abdominal obesity using computed tomography. International Journal of Obesity. 13:1989;289-303.
36. Sjostrom L. A computer-tomography based multi-compartment body composition technique and anthropometric predictions of lean body mass, total and subcutaneous adipose tissue. International Journal of Obesity. 64(Suppl. 15):1991;19-30.
37. Stanton J.M. Weight gain associated with neuroleptic medication: a review. Schizophrenia Bulletin. 21:1995;463-472.
38. Statistical Graphics Corporation:1993;Statgraphics, New York. Version 7. 0 New York. 1993.
39. Swett C., Noones J. Factors associated with premature termination from outpatient treatment. Hospital and Community Psychiatry. 40:1989;947-951.
40. Taylor D.M., McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavia. 101:2000;416-432.
41. Thakore J.H., Dinan T.G. Are blunted dexamethasone-induced growth hormone responses specific for depression? Psychological Medicine. 26:1996;1053-1059.
42. Thakore J.H., Mann J.N., Vlahoos J., Martin A., Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. International Journal of Obesity. 26:2002;137-141.
43. Thakore J.H., Richards P.J., Reznek R.H., Martin A., Dinan T.G. Increased intraabdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biological Psychiatry. 41:1997;1140-1142.
44. Van Cauter E., Linkowski P., Kerkhofs M., Hubain H.P., L'Hermite-Baleriaux M., Leclercq R., Brasseur M., Copinschi G., Mendelwicz J. Circadian and sleep-related endocrine rhythms in schizophrenia. Archives of General Psychiatry. 48:1991;348-356.
45. Wajchenberg B.L., Bosco A., Marone M.M., Levin S., Rocha M., Lerario A.C., Nery M., Goldman J., Liberman B. Estimation of body fat and lean tissue distribution by dual energy X-ray absorpitometry and abdominal body fat evaluation by computed tomography in Cushing's disease. Journal of Clinical Endocrinology and Metabolism. 80:1995;2791-2794.
46. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocrine Reviews. 21:2000;697-738.
47. Weber-Hamann B., Hentschel F., Kniest A., Deuschle M., Colla M., Lederbogen F., Heuser I. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosomatic Medicine. 64:2002;274-277.
48. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA in subjects with schizophrenia and mood disorder. Molecular Psychiatry. 7:2002;985-994.